AMR report depicts industry commitment
Medicines for Europe is among the healthcare industry stakeholders who have welcomed the first report on antimicrobial resistance (AMR) by the AMR Industry Alliance, which “brings together over 100 biotech, diagnostics, generics and research-based biopharmaceutical companies and trade associations from 20 countries” and shows that “broadly the Alliance membership is already active and making positive contributions to the challenge of AMR”.
You may also be interested in...
Generics firms have a crucial role to play in the fight against antimicrobial resistance, Thomas Cueni, chair of the AMR Industry Alliance, tells Generics Bulletin in an exclusive interview.
Access to expedited regulatory pathways, marketing exclusivity and tax credits in exchange for enrolling and retaining diverse clinical trial populations could provide a ‘carrot’ to the ‘stick’ in US FDA guidance and legislative proposals; attorneys Sarah Thompson Schick and Winston Kirton also call for a re-examination of concerns about remuneration for trial participants.
CBER Director Peter Marks said more sophisticated manufacturing expected in the next decade could lead to questions about whether gene therapies should be regulated by his center or CDRH.